D
DNALite
An early-stage preclinical biotechnology company that is making DNA based gene-therapy drugs for the gastrointestinal (GI) tract by leveraging new drug delivery technologies
About DNALite
DNAlite Therapeutics, Inc. is an early-stage preclinical biotechnology company focused on developing innovative gene therapies. The company leverages proprietary vector technology to create oral and non-immunogenic medicines aimed at overcoming the limitations of current biological treatments. DNAlite's primary objective is to modify the gastrointestinal (GI) tract to restore its functionality in patients with genetic diseases or compromised mucosa. By targeting GI cells with DNA and RNA, the company aims to address both intestinal and systemic diseases. DNAlite operates in the biotechnology sector, serving patients with genetic and GI-related conditions. Its business model revolves around the research and development of novel gene therapies, with revenue generation expected from licensing agreements, partnerships, and eventual commercialization of its therapeutic products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- San Francisco, United States
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 83.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Gastroenterology, Genetics and genomics, Genome Engineering, Digestion, Biotech and Pharma, Hard Tech, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning DNALite.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| CONVERTIBLEEquity / VC | Mar 2023 | $0 | — | SOSV · Indie Bio | — |
| EARLY VC✓Equity / VC | May 2022 | $8.9M | $36M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for DNALite is 270 monthly website visits, up 12.5% over the last three months. DNALite's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
SOSV
Indie Bio
Berkeley Catalyst Fund- BVBlue Bear Ventures
US National Science Foundation
Other known investors3 additional known investors
SeedFolio
SVE Capital- SCSVE Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about DNALite on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See DNALite’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.